Q2 FY26 results: Revenue up 7%, PAT up 18%, Re.1 interim dividend

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹701.90

prior close

₹711.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+4.0% vs market

Pharmaceuticals peers, median of 157sector-0.2%+4.0% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.7

10m

+2.8

15m

+3.5

30m

+3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7-0.3+4.0-0.2+4.0

Next day

+1.3+0.7+0.7+0.5+0.8

+1.3+0.6+0.7+0.6+0.8

+3.0+0.5+2.5+0.3+2.7

+1.2+1.1+0.1+0.2+1.0

+0.3+0.3+0.0-0.6+0.9

-0.3-0.2-0.0-1.1+0.8

15d

-4.1-2.2-1.9-2.0-2.2

-7.5-4.9-2.6-2.9-4.7

-13.1-7.5-5.6-5.8-7.2

-7.5-4.8-2.7-6.4-1.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amrutanjan Health Care reported Q2 FY26 revenue of Rs 117.7 crore (up 7.1% YoY) and PAT of Rs 13.96 crore (up 18.4% YoY). Basic EPS at Rs 4.83 versus Rs 4.08 last year. For H1 FY26, revenue grew 9.3% to Rs 211.7 crore and PAT surged 35.7% to Rs 22.27 crore. PBT margins expanded to 13.8% from 11% YoY, aided by lower other expenses ratio. OTC Products segment drove growth while Beverages stayed in loss. Board declared a first interim dividend of Re.1 per share. Statutory auditors B S R & Co. LLP issued an unmodified limited review report.

Likely market impact

Strong H1 earnings beat with PAT up 35.7% and margin expansion. Interim dividend signals management confidence; OTC segment leads, Beverages still weak.